Our Technology

Our drug design technology leverages a proprietary understanding of Integrin target dynamics (biophysical, structural and computational), enabling a new class of integrin inhibitors.

Morphic Therapeutic molecules are designed to prevent integrins from achieving disease-specific signaling through stabilization of appropriate conformations – even reversing integrin activation.

Cell Structures

The majority of integrins have been refractory to structural characterization, due to heavily glycosylated, heterodimeric metalloproteins composed of many flexible domains and interdomain linkers.

Morphic Therapeutic has exclusive rights to the Springer laboratory approach that allows robust determination of structures of integrin heterodimers (over 30 high-resolution integrin structures).

This knowledge has enabled the identification of proprietary chemotypes that control integrin conformations

By using in vitro biophysical techniques, enabled by proprietary protein reagents discovered in the Springer lab, Morphic Therapeutic scientists measure the conformational states of integrins to validate their antagonist properties.

Morphic Therapeutic established an exclusive integrin partnership with Schrödinger, the leader in chemical simulation and in silico drug discovery, which allows us to design, iterate, and optimize leads using a variety of next-generation physics-based technologies, in close collaboration with their Dedicated Drug Discovery Applications Group (DDAG).  Our partnership with Schrödinger LLC® enables us to design molecules with atomic precision utilizing state of art structure-guided drug design technology with the following key software technologies:

Our partnership with Schrödinger LLC® enables us to design molecules with atomic precision utilizing state of the art structure-guided drug design technology with the following key software technologies: FEP+ for free energy calculation; Glide for ligand-receptor binding; Induced Fit for prediction of ligand induced conformational changes in receptor active sites; and WaterMap for ligand optimization – to name a few.

All Rights Reserved and Copyright © 2016 | Morphic Therapeutic